Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma

The combination of dabrafenib and trametinib demonstrated encouraging antitumor activity and tolerability, at initial analysis, in Japanese patients with BRAF V600 mutant advanced melanoma warranting further investigation. This study evaluated the safety and tolerability, pharmacokinetics (PK) and p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Dermatol
Autors principals: Yamazaki, Naoya, Tsutsumida, Arata, Takahashi, Akira, Namikawa, Kenjiro, Yoshikawa, Shusuke, Fujiwara, Yutaka, Kondo, Shunsuke, Mukaiyama, Akihira, Zhang, Fanghong, Kiyohara, Yoshio
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947742/
https://ncbi.nlm.nih.gov/pubmed/29399853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.14210
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars